Veradermics' oral minoxidil lifts hair counts in 500-plus men over a year

Veradermics, a US company, has put a first set of one-year efficacy numbers behind VDPHL01, its investigational extended-release oral version of minoxidil for male pattern hair loss. The company reported the Part B results of its Phase 2/3 Study '302' on 9 November 2026. The trial enrolled more than 500 men with mild-to-moderate disease.

Men taking the drug twice daily gained 43.9 non-vellus (terminal) hairs per square centimetre from baseline. The once-daily group gained 29.7. Veradermics did not provide figures for the comparator arms in the material reviewed, so the size of the benefit over control cannot be judged yet.

On safety, the company says the trial recorded no serious adverse events attributed to treatment, no cardiac events it had flagged for special monitoring, and no new safety signals. It has not published the definition of those cardiac events or the full adverse-event rates. Cardiovascular tolerability is the obvious scrutiny point for an oral drug built on minoxidil, which has a long history as a blood-pressure medicine (general context, not from the company).

Veradermics says the dataset supports a route to US approval but has not given a submission timetable. The next catalyst is Study '306' in female pattern hair loss, with data expected in the first half of 2027. That readout will show whether the company can pursue a patient population beyond men. No pricing, partnering or revenue information accompanied the announcement.